Recursion Pharmaceuticals (NASDAQ:RXRX) Director Blake Borgeson Sells 40,000 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 40,000 shares of the stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $3.88, for a total transaction of $155,200.00. Following the transaction, the director directly owned 6,068,287 shares of the company’s stock, valued at approximately $23,544,953.56. This trade represents a 0.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, October 6th, Blake Borgeson sold 50,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $4.84, for a total value of $242,000.00.
• On Tuesday, September 1st, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $3.34, for a total value of $100,200.00.

Recursion Pharmaceuticals Stock Up 5.4%

RXRX stock opened at $3.88 on Thursday. The business has a 50 day moving average price of $3.77 and a 200 day moving average price of $3.53. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of -4.31 and a beta of 1.15. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $2.77 and a fifty-two week high of $5.24.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Monday, November 2nd. The company reported ($0.22) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.22). The company had revenue of $18.55 million for the quarter, compared to analysts’ expectations of $14.81 million. Recursion Pharmaceuticals had a negative net margin of 697.15% and a negative return on equity of 47.85%. During the same quarter last year, the company earned ($0.36) earnings per share. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -0.93 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in RXRX. Ascent Wealth Partners LLC increased its stake in Recursion Pharmaceuticals by 11.8% in the first quarter. Ascent Wealth Partners LLC now owns 28,081 shares of the company’s stock valued at $86,000 after purchasing an additional 2,974 shares during the period. Cherry Creek Investment Advisors Inc. raised its stake in shares of Recursion Pharmaceuticals by 5.8% during the 1st quarter. Cherry Creek Investment Advisors Inc. now owns 70,536 shares of the company’s stock worth $217,000 after buying an additional 3,859 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Recursion Pharmaceuticals by 33.2% in the first quarter. PNC Financial Services Group Inc. now owns 16,832 shares of the company’s stock valued at $52,000 after acquiring an additional 4,199 shares during the period. Sequoia Financial Advisors LLC boosted its holdings in Recursion Pharmaceuticals by 51.5% during the first quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock worth $47,000 after buying an additional 5,156 shares in the last quarter. Finally, Axxcess Wealth Management LLC grew its position in Recursion Pharmaceuticals by 16.6% during the first quarter. Axxcess Wealth Management LLC now owns 37,516 shares of the company’s stock worth $115,000 after buying an additional 5,338 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Wall Street Analysts Forecast Growth

RXRX has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, October 15th. Morgan Stanley set a $5.90 price objective on shares of Recursion Pharmaceuticals in a research note on Friday, October 16th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Monday, October 19th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.18.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.